Protagonist Therapeutics, Inc.
PTGX
Rangering i aksjer
#2254
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aksjekurs
$138.50
Sist synkronisert: 2026-10-20
Markedsverdi
$8.96B
Endring (1 dag)
3.02%
Endring (1 år)
84.67%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
P/S-forhold for Protagonist Therapeutics, Inc. (PTGX)
P/S-forhold per October 2026 TTM: 31.27
Ifølge Protagonist Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 31.27. Ved slutten av 2023 hadde selskapet et P/S-forhold på 21.69.
P/S-historikk for Protagonist Therapeutics, Inc. fra 2014 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 31.27 | 471.70% |
| 2024 | 5.47 | -74.78% |
| 2023 | 21.69 | 7.77% |
| 2022 | 20.13 | -65.24% |
| 2021 | 57.91 | 139.08% |
| 2020 | 24.22 | -96.93% |
| 2019 | 790.27 | 16,137.36% |
| 2018 | 4.87 | -73.47% |
| 2017 | 18.34 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | -67.95% |
US
|
|
| 40.55 | 29.67% |
US
|
|
| 3.96 | -87.33% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -67.55% |
NL
|
